Last reviewed · How we verify

Lipiodol UltraFluid — Competitive Intelligence Brief

Lipiodol UltraFluid (Lipiodol UltraFluid) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Iodized contrast agent / embolic agent. Area: Oncology.

marketed Iodized contrast agent / embolic agent Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Lipiodol UltraFluid (Lipiodol UltraFluid) — Amsterdam UMC, location VUmc. Lipiodol UltraFluid is an iodized poppy seed oil contrast agent that accumulates in hepatic lesions and provides both diagnostic imaging and therapeutic embolization.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lipiodol UltraFluid TARGET Lipiodol UltraFluid Amsterdam UMC, location VUmc marketed Iodized contrast agent / embolic agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Iodized contrast agent / embolic agent class)

  1. Amsterdam UMC, location VUmc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lipiodol UltraFluid — Competitive Intelligence Brief. https://druglandscape.com/ci/lipiodol-ultrafluid. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: